ATXS

Astria Therapeutics Inc

Jan 22 • 04:00PM ET

12.58

0.00 0.00 %

Healthcare • Biotechnology • USA • NASD

Peers: REGN VRTX PFE GILD AMGN BIIB SRPT ALNY NBIX BLUE

| Held by: VTI VXF VTWO ARB VHT VTWV EVNT VTHR BTEC

Index	RUT	P/E	-	EPS (ttm)	-2.15	Insider Own	12.34%	Shs Outstand	56.43M	Perf Week	0.32%
Market Cap	718.13M	Forward P/E	-	EPS next Y	-2.39	Insider Trans	0.00%	Shs Float	50.04M	Perf Month	-1.95%
Enterprise Value	590.19M	PEG	-	EPS next Q	-0.54	Inst Own	82.26%	Short Float	11.50%	Perf Quarter	3.45%
Income	-124.03M	P/S	1011.45	EPS this Y	-31.75%	Inst Trans	-18.62%	Short Ratio	5.31	Perf Half Y	88.32%
Sales	0.71M	P/B	5.15	EPS next Y	-8.13%	ROA	-39.16%	Short Interest	5.75M	Perf YTD	-3.90%
Book/sh	2.44	P/C	3.15	EPS next 5Y	-5.63%	ROE	-43.15%	52W High	13.29 -5.34%	Perf Year	66.18%
Cash/sh	3.99	P/FCF	-	EPS past 3/5Y	59.12% 34.65%	ROIC	-52.49%	52W Low	3.56 253.87%	Perf 3Y	-11.22%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	0.00%	Volatility	2.11% 1.68%	Perf 5Y	-22.63%
Dividend TTM	-	EV/Sales	831.25	EPS Y/Y TTM	-2.74%	Oper. Margin	-19335.69%	ATR (14)	0.23	Perf 10Y	-96.78%
Dividend Ex-Date	-	Quick Ratio	10.78	Sales Y/Y TTM	-	Profit Margin	-17567.99%	RSI (14)	46.09	Recom	3.00
Dividend Gr. 3/5Y	- -	Current Ratio	10.78	EPS Q/Q	-28.56%	SMA20	-1.78%	Beta	0.20	Target Price	13.00
Payout	-	Debt/Eq	0.02	Sales Q/Q	-	SMA50	-1.30%	Rel Volume	0.00	Prev Close	12.58
Employees	78	LT Debt/Eq	0.01	Earnings	Nov 12 BMO	SMA200	51.97%	Avg Volume	1.08M	Price	12.58
IPO	Jun 25, 2015	Option/Short	Yes / No	EPS/Sales Surpr.	-40.77% -93.38%	Trades		Volume	0	Change	0.00%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-12-25	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Sep-17-25	Reiterated	H.C. Wainwright	Buy	$16 → $20
Apr-29-25	Initiated	Cantor Fitzgerald	Overweight	$47
Jan-31-25	Initiated	JMP Securities	Mkt Outperform	$26
Jul-29-24	Initiated	TD Cowen	Buy	$35
Mar-28-23	Initiated	Evercore ISI	Outperform	$18

Jan-21-26 04:00PM	Astria Stockholders Vote to Approve Acquisition by BioCryst (Business Wire)
Jan-08-26 12:50PM	Halper Sadeh LLC Encourages CSGS, JHG, CWAN, ATXS Shareholders to Contact the Firm to Discuss Their Rights (PR Newswire)
Dec-01-25 06:59PM	Halper Sadeh LLC Encourages RNA, TCBX, ATXS, FSUN Shareholders to Contact the Firm to Discuss Their Rights (PR Newswire)
Nov-12-25 01:55PM	Halper Sadeh LLC Encourages HSII, MRUS, ATXS Shareholders to Contact the Firm to Discuss Their Rights (PR Newswire)
09:10AM	Astria Therapeutics, Inc. (ATXS) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
08:00AM	Loading…
08:00AM	Astria Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update (Business Wire)
Nov-06-25 08:00AM	Astria Therapeutics Announces Final Positive Results from All Enrolled HAE Patients in the ALPHA-STAR Phase 1b/2 Trial of Navenibart (Business Wire)
Oct-31-25 05:42PM	Astria, Viridian Therapeutics, and More Stocks See Action From Activist Investors (Barrons.com)
08:00AM	Astria Therapeutics to Present at Upcoming American College of Allergy, Asthma, and Immunology Annual Scientific Meeting (Business Wire)
Oct-15-25 10:05AM	Astria Therapeutics Stock Rallies 37% on $700M Buyout Offer From BCRX (Zacks)
05:16AM	BioCryst to buy Astria Therapeutics for $700m in enterprise value (Pharmaceutical Technology)
Oct-14-25 07:32AM	BioCryst goes all in on rare swelling disease with Astria deal (BioPharma Dive) +37.07%
07:00AM	BioCryst to Acquire Astria Therapeutics, Strengthening Presence in HAE, Transforming Growth Profile (Business Wire)
Oct-11-25 12:00PM	3 Biotech Stocks That Could More Than Triple if Their Trials Succeed (Barchart)
Oct-09-25 08:00AM	Astria Therapeutics to Present at Upcoming CSACI 80th Anniversary Scientific Meeting (Business Wire)
08:00AM	Loading…
Oct-08-25 08:00AM	Astria Therapeutics Initiates the Phase 3 ORBIT-EXPANSE Long-Term Trial of Navenibart in People with Hereditary Angioedema (Business Wire) +12.45%
Oct-03-25 08:00AM	Astria Therapeutics to Present at Upcoming 2025 HAEi Regional Conference EMEA (Business Wire)
Oct-02-25 04:10PM	Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
08:00AM	Astria Therapeutics Now Enrolling HAE Patients in the European Union for the Phase 3 ALPHA-ORBIT Trial (Business Wire)
Sep-17-25 08:00AM	Astria Therapeutics Announces Positive Initial Results from the Phase 1a Healthy Subject Trial of STAR-0310 at the European Academy of Dermatology and Venereology (Business Wire)
Sep-11-25 12:00PM	All You Need to Know About Astria Therapeutics (ATXS) Rating Upgrade to Buy (Zacks)
Sep-09-25 09:55AM	Wall Street Analysts Believe Astria Therapeutics (ATXS) Could Rally 294.75%: Here's is How to Trade (Zacks)
Sep-08-25 05:03PM	Astria Therapeutics, Inc. (ATXS) Now Trades Above Golden Cross: Time to Buy? (Zacks)
Sep-03-25 04:10PM	Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +6.07%
08:00AM	Astria Therapeutics to Present Initial Data from Phase 1a Trial of STAR-0310 at Upcoming European Academy of Dermatology & Venereology Congress 2025 (Business Wire)
Sep-02-25 07:30AM	2 Strong Buy Growth Stocks Offering 300% or Higher Upside (Barchart) +6.63%
Aug-27-25 08:00AM	Astria Therapeutics to Present at Upcoming Cantor Global Healthcare Conference (Business Wire)
Aug-15-25 09:55AM	Does Astria Therapeutics (ATXS) Have the Potential to Rally 333.88% as Wall Street Analysts Expect? (Zacks)
Aug-12-25 04:10PM	Astria Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Corporate Update (Business Wire)
Aug-07-25 05:55AM	Astria Therapeutics licenses navenibart rights to Kaken for HAE (Pharmaceutical Technology)
08:00AM	Loading…
Aug-06-25 08:00AM	Astria Therapeutics Enters into Licensing Agreement with Kaken Pharmaceutical to Develop and Commercialize Navenibart for HAE in Japan (Business Wire)
Aug-04-25 04:10PM	Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +5.03%
Jul-31-25 11:40PM	Astria Therapeutics Announces Positive Initial Results from Long-Term Navenibart Trial in HAE Patients (Insider Monkey) -5.20%
Jul-07-25 08:00AM	Astria Therapeutics to Present at Upcoming 2025 US Hereditary Angioedema Association National Summit (Business Wire) +6.71%
Jul-02-25 04:10PM	Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +5.52%
Jun-18-25 08:00AM	Astria Therapeutics to Participate in Upcoming Oppenheimer Innovators in Immunology & Inflammation Summit (Business Wire)
Jun-13-25 07:00AM	Astria Therapeutics Announces Positive Initial Results from the ALPHA-SOLAR Long-Term Open-Label Trial of Navenibart in Hereditary Angioedema Patients at the European Academy of Allergy and Clinical Immunology Annual Congress (Business Wire)
Jun-06-25 08:00AM	Astria Therapeutics to Present at Upcoming European Academy of Allergy and Clinical Immunology Annual Congress (Business Wire) +14.75%
Jun-03-25 04:10PM	Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +6.45%
May-28-25 08:00AM	Astria Therapeutics to Present at Upcoming Jefferies Global Healthcare Conference (Business Wire) +6.85%
May-23-25 08:00AM	Astria Therapeutics to Present at Upcoming C1 Inhibitor Deficiency and Angioedema Workshop (Business Wire)
May-22-25 08:00AM	Astria Therapeutics to Present at Upcoming Eastern Allergy Conference (Business Wire)
May-13-25 04:10PM	Astria Therapeutics Reports First Quarter 2025 Financial Results and Provides a Corporate Update (Business Wire) -10.76%
May-09-25 08:30AM	Is Astria Therapeutics, Inc. (ATXS) the Low Risk High Reward Stock Set to Triple by 2030? (Insider Monkey)
May-02-25 04:10PM	Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
May-01-25 08:00AM	Astria Therapeutics Announces Publication of Navenibart Phase 1a Healthy Subject Results in the Annals of Allergy, Asthma & Immunology (Business Wire)
Apr-30-25 08:00AM	Astria Therapeutics to Present at Upcoming Citizens Life Sciences Conference (Business Wire)
Apr-02-25 04:10PM	Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -6.70%
Mar-11-25 08:00AM	Astria Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Corporate Update (Business Wire) +11.17%
Mar-04-25 04:10PM	Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Feb-27-25 08:00AM	Astria Therapeutics Initiates ALPHA-ORBIT Phase 3 Pivotal Trial of Navenibart in Hereditary Angioedema (Business Wire)
Feb-25-25 08:00AM	Astria Therapeutics to Present at Upcoming TD Cowen 45th Annual Health Care Conference (Business Wire)
Feb-20-25 08:00AM	Astria Therapeutics to Present at Upcoming American Academy of Allergy, Asthma and Immunology and World Allergy Organization Joint Congress (Business Wire)
Feb-04-25 04:10PM	Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
08:00AM	Astria Therapeutics to Present at Upcoming Oppenheimer 35th Annual Healthcare Life Sciences Conference (Business Wire)
Feb-03-25 08:00AM	Astria Therapeutics to Present at Upcoming Western Society of Allergy, Asthma & Immunology Annual Scientific Session (Business Wire) -5.47%
Jan-23-25 08:00AM	Astria Therapeutics Announces Initiation of Phase 1a Trial of STAR-0310, a Potential Best-in-Class Monoclonal Antibody OX40 Antagonist for the Treatment of Atopic Dermatitis (Business Wire)
Jan-13-25 08:00AM	Astria Therapeutics Announces Design of ALPHA-ORBIT Pivotal Phase 3 Trial of Navenibart in HAE (Business Wire)
Jan-03-25 04:10PM	Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Dec-11-24 08:00AM	Astria Therapeutics Announces Positive Final Results from Target Enrollment in the ALPHA-STAR Phase 1b/2 Trial of Navenibart for HAE (Business Wire)
Dec-10-24 08:00AM	Astria Therapeutics Announces FDA Clearance of IND Application for STAR-0310, a Monoclonal Antibody OX40 Antagonist for the Treatment of Atopic Dermatitis (Business Wire)
Dec-03-24 04:10PM	Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Nov-13-24 04:10PM	Astria Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update (Business Wire)
08:00AM	Astria Therapeutics to Present at Upcoming Jefferies London Healthcare Conference (Business Wire)
Nov-04-24 04:10PM	Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Oct-30-24 08:00AM	Astria Therapeutics to Present at Upcoming Canadian Society of Allergy and Clinical Immunology Annual Scientific Meeting (Business Wire)
Oct-21-24 08:00AM	Astria Therapeutics to Present at Upcoming American College of Allergy, Asthma, and Immunology Annual Scientific Meeting (Business Wire)
Oct-17-24 08:16AM	Astria Therapeutics' navenibart gains orphan medicinal status from EC (Pharmaceutical Business Review)
Oct-16-24 08:00AM	European Commission Grants Orphan Medicinal Product Designation for Navenibart, Astria Therapeutics Investigational Therapy for the Treatment of Hereditary Angioedema (Business Wire)
Oct-02-24 04:10PM	Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-30-24 08:00AM	Astria Therapeutics Receives FDA Orphan Drug Designation for Navenibart (STAR-0215) for the Treatment of Hereditary Angioedema (Business Wire)
Sep-27-24 08:00AM	Astria Therapeutics to Present at Upcoming Global Angioedema Forum (Business Wire)
Sep-19-24 08:00AM	Astria Therapeutics to Present at Upcoming European Academy of Dermatology and Venerology Congress (Business Wire) +6.37%
Sep-04-24 04:10PM	Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Aug-30-24 08:00AM	Astria Therapeutics to Present at Upcoming Bradykinin Symposium (Business Wire)
Aug-29-24 08:00AM	Astria Therapeutics to Participate in Upcoming Morgan Stanley 22nd Annual Global Healthcare Conference (Business Wire)
Aug-12-24 04:10PM	Astria Therapeutics Reports Second Quarter 2024 Financial Results and Provides a Corporate Update (Business Wire) +7.48%
04:00PM	Astria Therapeutics Chooses Ypsomed's YpsoMate as the Injection Device for STAR-0215 for the Treatment of Hereditary Angioedema (Business Wire)
Aug-07-24 08:00AM	Astria Therapeutics to Participate in Upcoming 2024 Wedbush PacGrow Healthcare Conference (Business Wire)
Aug-02-24 04:10PM	Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -6.61% -5.36%
Jul-02-24 04:10PM	Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jun-04-24 04:10PM	Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
May-30-24 08:00AM	Astria Therapeutics to Present at Upcoming Jefferies Healthcare Conference (Business Wire)
May-24-24 08:00AM	Astria Therapeutics to Present at Upcoming Eastern Allergy Conference (Business Wire)
May-23-24 08:00AM	Astria Therapeutics to Present at Upcoming European Academy of Allergy and Clinical Immunology Congress (Business Wire)
May-09-24 04:10PM	Astria Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update (Business Wire) +6.27%
May-08-24 08:00AM	Astria Therapeutics to Present at Upcoming Society for Investigative Dermatology Annual Meeting (Business Wire)
May-02-24 04:00PM	Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Apr-09-24 08:00AM	Astria Therapeutics Appoints Sunil Agarwal to Its Board of Directors (Business Wire)
Apr-03-24 07:00PM	Chief Medical Officer Christopher Morabito Sells 10,000 Shares of Astria Therapeutics Inc (ATXS) (GuruFocus.com) -5.47%
04:10PM	Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Mar-25-24 07:30AM	Astria Therapeutics Announces Positive Initial Proof-of-Concept Results from the ALPHA-STAR Phase 1b/2 Trial of STAR-0215 for HAE (Business Wire)
Mar-05-24 04:10PM	Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +6.14%
Mar-04-24 10:52PM	ATXS Stock Earnings: Astria Therapeutics Misses EPS for Q4 2023 (InvestorPlace)
04:10PM	Astria Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update (Business Wire)
Feb-29-24 03:02AM	14 Stocks With Heavy Insider Buying In 2024 (Insider Monkey)
Feb-20-24 08:00AM	Astria Therapeutics to Present at Upcoming American Academy of Allergy, Asthma & Immunology Annual Meeting (Business Wire)
Feb-06-24 08:00AM	Astria Therapeutics to Present at Upcoming Oppenheimer 34th Annual Healthcare Life Sciences Conference (Business Wire) +6.25%
Feb-05-24 04:00PM	Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +6.95%
Jan-30-24 07:29PM	Chief Medical Officer Christopher Morabito Sells 10,000 Shares of Astria Therapeutics Inc (GuruFocus.com) +6.62%

Astria Therapeutics, Inc. engages in the discovery, development, and commercialization of novel therapeutics. Its lead product candidate is STAR-0215, which is intended to treat Hereditary Angioedema, a rare genetic disorder characterized by severe, recurrent, unpredictable, painful, and sometimes life-threatening swelling in the face, limbs, abdomen, and airway. The company was founded by Michael R. Jirousek, Jill C. Milne and Steven E. Shoelson on June 26, 2008 and is headquartered in Boston, MA.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ATXS

Astria Therapeutics Inc

Upgrade your FINVIZ experience